Reckitt Benckiser disappoints but headwinds should ease

Josh White WebFG News | 21 Apr, 2017 08:19 - Updated: 12:01 | | |

Reckitt Benckiser, consumer goods, Cillit Bang, Vanish
  • 6,763.00
  • 0.45%30.00
  • Max: 6,780.00
  • Min: 6,710.00
  • Volume: 1,581,209
  • MM 200 : n/a
17:30 12/12/17
  • 7,500.41
  • 0.63%46.93
  • Max: 7,501.52
  • Min: 7,448.31
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,167.58
  • 0.53%21.93
  • Max: 4,167.95
  • Min: 4,143.15
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,114.09
  • 0.53%21.50
  • Max: 4,114.10
  • Min: 4,090.46
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17
  • 18,204.90
  • -0.09%-16.51
  • Max: 18,252.39
  • Min: 18,060.25
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17

Consumer products group Reckitt Benckiser posted a trading update for its first quarter on Friday, reporting it was in line with expectations with continued strong performance in the health division led by Mucinex and Durex.

However, sales in the quarter were slightly behind analyst consensus as negative like-for-like sales in Europe were offset by growth in developing markets and foods.

The FTSE 100 firm said that growth was offset by headwind in Scholl/Amopé, which also impacted Europe-North America performance.

Growth rates were set to improve through the year, and RB said it was on track for its full year net revenue target of 3% like-for-like.

The company said home and portfolio categories, and the DvM emerging market area, were negatively impacted by what the it called the “Korea HS issue”, whereby it was still dealing with the legacy of faulty Oxy RB-branded humidity sterilisers distributed in the 1990s and 2000s that caused a number of deaths.

The Mead Johnson acquisition remained on track for completion by the end of the third quarter, it added, and confirmed the strategic review of the Food business had commenced.

“Our Q1 results are in line with expectations as macro conditions remain challenging,” said CEO Rakesh Kapoor.

“Against this backdrop our underlying business remains strong.”

Kapoor said RB delivered continued outperformance in consumer health and good growth in DvM, offset by previously flagged headwinds, which would persist during the first half.

“I expect our growth trajectory to improve as we progress through the year and we remain on track to achieve our full year net revenue target of 3% LFL growth.”

Charlie Huggins, a fund manager for Hargreaves Lansdown, said it was the first quarter he can remember where the group has failed to grow its like-for-like sales and that most of the headwinds should ease as the year progresses.

"We don’t think for one minute that Reckitt’s brands are losing their fundamental appeal, or that the company has lost its ability to innovate.

"We expect this brand strength, supported by the company’s huge marketing clout, to drive growth in the longer term. The investment case also depends on Reckitt’s ability to integrate the Mead Johnson acquisition, which is expected to complete at the end of the third quarter."

More news

12 Dec US close: Markets mixed as Fed finishes first day of meeting

Wall Street's main indices finished mixed on Tuesday as the Federal Reserve kicked off its two-day rate-setting meeting, alongside several positive updates from corporate heavyweights such as Boeing and 3M.

12 Dec Theresa May unveils new climate change policies in Paris summit

Prime Minister Theresa May has announced new environmental policies including a £140m fund to help developing countries battle against the negative effects of climate change.

12 Dec Broker tips: Lloyds, Barclays, Entertainment One

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.

12 Dec Results round-up

Industrial equipment rental firm Ashtead said half year earnings were boosted by clean-up efforts after hurricanes Harvey, Irma and Maria and the weak pound as it posted a 16% rise in pre-tax profits to £493.1m.

12 Dec Europe close: Technology and M&A power gains in shares

Stocks on the Continent gained ground on Tuesday paced by Technology issues, even as traders waited on the US central bank's policy announcement the next day.

12 Dec London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

12 Dec US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

12 Dec EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

12 Dec Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

12 Dec GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.